Shenzhen Microprofit Biotech Unveils All-in-One Viral and Mycoplasma Pneumoniae Test Kit

Shenzhen Microprofit Biotech Co., Ltd., a leading player in the biotech industry, has recently launched its innovative fluorecare® SARS-CoV-2/RhV/PIV/Influenza A/B/RSV/ADV/hMPV/M.P Antigen Combo Test Kit. This cutting-edge product, with the reference number MF-139, is designed to detect up to 9 different pathogens, revolutionizing the field of infectious disease diagnosis.

The kit utilizes the Colloidal Gold Chromatographic Immunoassay method, ensuring high accuracy, sensitivity, and specificity. This means that it can precisely identify the presence of various viruses and Mycoplasma pneumoniae, providing reliable results for medical professionals and patients alike. One of the most remarkable features of this test kit is its rapidity. It can generate results within just 12 minutes, enabling swift decision - making in clinical settings. This is a significant improvement over traditional testing methods that often require longer waiting times.

In addition to its speed and accuracy, the fluorecare® test kit has an impressive 24 - month shelf life when stored between 2 - 30°C. This long shelf life makes it more convenient for storage and distribution, reducing waste and ensuring a stable supply. It accepts multiple sample types, including oropharyngeal swabs, nasal swabs, and nasopharyngeal swabs, providing flexibility in sample collection.

Available in specifications of 1 Test/box and 25 Tests/box, the product is cost - effective, making it accessible for a wide range of users, from small medical clinics to large - scale testing centers. With this new test kit, Microprofit Biotech aims to enhance the efficiency of disease diagnosis, especially in the context of the ongoing global health challenges. This product not only simplifies the testing process but also contributes to better disease control and management. As the demand for fast and reliable pathogen detection continues to grow, the fluorecare® MF - 139 test kit is set to play a crucial role in the future of infectious disease diagnosis.